C O M M E N TA R Y
Centers for Disease Control published a treatment algorithm for hypertension recommendations in November 2013. 9 Shortly after, in December 2013, the American Society of Hypertension published guidelines jointly with the International Society of Hypertension. 10 This was followed by the JNC 8 recommendations, which were released online in December 2013. 4 The simultaneous publication of 3 hypertension guidelines is rare. The risk of multiple guideline publications over 3 months for 1 diagnosis is that busy clinicians, already confronted with information overload, will have limited time to adequately appraise the quality of the recommendations. 5 
JNC 8 is different from previous JNC reports.
The JNC 8 panel adhered to the Institute of Medicine's (IOM) call to develop guidelines using a consistent process in order to foster development of high-quality, trustworthy products. 4, 11, 12 Some key changes in JNC 8 include use of a systematic review procedure for data identification and extraction and incorporation of external reviewers. Another notable change is the inclusion of only randomized controlled trials (RCTs) as the basis for JNC 8's recommendations. These changes have been received with mixed reviews from the medical community and have been the focal point of criticism and praise. [6] [7] [8] Indeed, these process changes distinguish JNC 8 from prior JNC reports, as well as from other contemporary hypertension guidelines.
JNC 8 is restricted to 3 critical questions about hypertension management.
The JNC 8 writing committee focused its recommendations on the areas of hypertension management that were considered to be high priority. The committee selected 3 questions and provided recommendations to these questions rather than provision of a set of all-encompassing guidelines.
systolic BP for patients aged between 60 and 79 years to < 150 mm Hg instead of < 140 mm Hg. Indeed, no RCT exists that prospectively evaluated clinical outcomes in patients targeted to a systolic BP of < 140 mm Hg compared with placebo or compared with a target of < 150 mm Hg. Although the JNC 8 recommendation is criticized, the recommendation from other guidelines to target systolic BP to < 140 mm Hg in patients aged between 60 and 79 years is largely based on observational, epidemiological, and post hoc analyses. 9, 10, 13 Thus, the lack of congruence between the guidelines for this particular example can be explained by the process utilized to develop the recommendation.
JNC 8 is not rivaling minority or dissenting views.
In the JNC 8 publication, the writing committee disclosed when panel members were unable to reach agreement. 4 The most notable recommendation in which this occurred was with regard to the relaxing the systolic BP goal in patients aged between 60 and 79 years. Here, the JNC 8 publication acknowledged the lack of unanimity among the panel members. To maximize transparency, those with the "minority view" published a detailed review of their perspective. 13 The process by which the minority opinion has been made known shows that the JNC 8 writing committee remained true to the recommendation from the IOM to add transparency to the process for guideline development, even when publishing recommendations unofficially.
■■ Conclusions
The landscape of hypertension guidelines has and will continue to change. The NHLBI-endorsed guidelines (JNC 1 through 7) are no longer going to be the clinician's foremost resource for all-inclusive hypertension prevention, diagnosis, and management recommendations. Adoption of the new guideline process naturally requires an adjustment period; however, acclimation to these changes has been complicated by concurrent publication of other hypertension guidelines that did not limit evidence review to only RCTs. Many question how to apply these new recommendations given that highly visible criticism, including a call to retract the JNC 8 publication, implies that the JNC 8 recommendations may be incomplete and myopic and introduces cynicism towards the process and product.
However, it is our assertion that the JNC 8 recommendations represent advancement in guideline development-introducing systematic review and peer review into the process augments reliability. Because JNC 8 recommendations were developed with a rigorous process, even the controversial recommendations (e.g., BP goals) should be appraised in the context of the total body of evidence and the needs of the individual patient. Conversely, the relegation of recommendations to 3 critical questions means that JNC 8 cannot exist as a
JNC 8 is the first contemporary hypertension guideline to apply only RCTs to its recommendations.
The evidence reviewed by the panel appointed to JNC 8 included only RCTs in order to provide strong recommendations that were based on robust evidence. 4 Because other guidelines include observational studies, meta-analyses, and systematic reviews, discordant recommendations should be expected, since the evidence reviewed is not parallel. 1, 9, 10, 13 Recognition that different evidence was evaluated to form the recommendations may allay frustration regarding discordant conclusions. Whether reviewing only RCTs or reviewing the evidence in total is preferred for guideline development is a complex question. One advantage of using only RCTs for recommendations is that the quality of the data is strong; therefore, the recommendations can be made with confidence. However, a wellknown disadvantage of restricting evidence is that exclusion of non-RCT data risks application of an "all-or-none" approach to literature assessment and potentially disregards the totality of the available evidence. The more traditional approach to development of guideline recommendations includes level-ofevidence statements to provide transparency about the quality of evidence supporting the recommendation, which mitigates risk of incorporating non-RCT data.
■■ What JNC 8 Is Not

JNC 8 is not an officially endorsed, sanctioned set of guidelines.
Importantly, although the JNC 8 writing panel retained the "JNC" title, its recommendations are not endorsed by the NHLBI as were the previous JNC reports. 4 While initially commissioned to provide updated hypertension guidelines by the NHLBI, the decision to not sanction or commission recommendations by the panel appointed to JNC 8 was made after the committee's work had essentially been completed. The JNC 8 panel chose to publish its findings independently to provide timely recommendations while the new official guidelines are being developed. 4 The distinction that JNC 8 is not endorsed, while prior JNC reports have been is important to recognize and leads to the next point.
JNC 8 is not the official hypertension guideline that replaces JNC 7.
When the NHLBI announced that it would transfer guideline development to external organizations, the AHA and ACC jointly accepted responsibility for this task. 3 It is anticipated that the official AHA/ACC guidelines that will replace JNC 7 will be made available in 2015. 14 
JNC 8 is not congruent with other hypertension guidelines.
Because the JNC 8 writing committee included only RCTs, discordance exists between the JNC 8 and other recently published guidelines. 4, 9, 10, 13 The most high-profile example of this is in regards to JNC 8's recommendation to relax the goal
